Related Experiment Video
Updated: Jul 16, 2026
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Angioedema in renal transplant recipients on sirolimus
Emmanuel Mahé1, Emmanuel Morelon, Sophie Lechaton
1Department of Dermatology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France. emmanuel.mahe@apr.aphp.fr
Background:
Most drug-associated angioedemas are induced by angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, or nonsteroidal anti-inflammatory drugs. Recently, the responsibility of immunosuppressive agents given to transplant recipients in the development of angioedema has been discussed.
Objective:
To describe, in detail, angioedema episodes in renal transplant recipients (RTRs) on sirolimus.
Methods:
A cross-sectional study in a university hospital. Eighty consecutive RTRs on sirolimus were studied.
Results:
Angioedema without urticaria occurred a mean of 5 times in 12/80 (15%) RTRs taking sirolimus. It was predominantly located on the face (83%), with mucous membrane involvement in 7 (58%) patients, and was life threatening in 1. Another putative cofactor for angioedema without urticaria was identified in 9 (75%) patients: drugs (n=8), food allergy or physical activity (n=3). Tacrolimus intake was significantly associated with sirolimus-associated angioedema.
Conclusion:
Our results suggested a causal relationship between sirolimus and angioedema in RTRs.
Related Concept Videos
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure
01:28Kidney Transplant I: Introduction
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...